Speaking with Generics Bulletin as Centrient announced this month that it had closed its deal to acquire Indian sterile injectables specialist Astral Steritech, Centrient CEO Rex Clements was clear on the transformative potential of the deal for the antibiotics, statins and anti-fungals producer.
“This is pretty fundamental for a few reasons,” Clements said of the acquisition that was announced earlier this year, which will allow the firm to diversify into sterile injectable antibiotics as well as bringing it a broader product portfolio and two US Food and Drug Administration-approved production lines